

Rury R Holman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2996959/rury-r-holman-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145
papers

23,143
citations

42
h-index

151
g-index

151
ext. papers

26,687
ext. citations

13.6
avg, IF

6.55
L-index

#	Paper	IF	Citations
145	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.. <i>Science Translational Medicine</i> , 2022 , 14, eabj9625	17.5	3
144	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. <i>Diabetes Research and Clinical Practice</i> , 2021 , 183, 109152	7.4	0
143	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2021 ,	14.6	2
142	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. <i>Atherosclerosis</i> , 2021 , 338, 1-6	3.1	2
141	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. <i>Lancet, The</i> , 2021 , 396, 2019-2082	40	90
140	Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance. <i>Journal of Diabetes</i> , 2021 , 13, 817-826	3.8	0
139	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021 , 38, e14552	3.5	2
138	Neck circumference and waist circumference associated with cardiovascular events in type 2 diabetes (Beijing Community Diabetes Study 23). <i>Scientific Reports</i> , 2021 , 11, 9491	4.9	1
137	Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 2580-2590	3.7	5
136	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021 , 44, 1877-1884	14.6	7
135	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis. <i>Annals of Internal Medicine</i> , 2021 , 174, 58-68	8	15
134	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1101-1110	6.7	1
133	Historical HbA Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. <i>Diabetes Care</i> , 2021 ,	14.6	6
132	Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). <i>Diabetic Medicine</i> , 2021 , 38, e14656	3.5	2
131	Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. <i>American Heart Journal</i> , 2021 , 239, 59-63	4.9	0
130	Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2021 ,	14.6	0
129	Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2022 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning. <i>Value in Health</i> , 2020 , 23, 1340-1348	3.3	1

128	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. <i>Diabetes Research and Clinical Practice</i> , 2020 , 170, 108488	7.4	3
127	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , 2020 , 40, 460-473	2.5	6
126	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. <i>Circulation</i> , 2020 , 141, 1360-1370	16.7	8
125	Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1151-1156	6.7	6
124	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. <i>Diabetes Care</i> , 2020 , 43, 2242-2247	14.6	4
123	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 2026-2034	12.3	9
122	Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 206-215	18.1	21
121	Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22). <i>Diabetes Therapy</i> , 2020 , 11, 887-898	3.6	0
120	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. <i>Circulation</i> , 2020 , 141, 843-862	16.7	25
119	β-cell secretory dysfunction: a key cause of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 370	18.1	3
118	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	14
117	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol. <i>BMJ Open</i> , 2020 , 10, e018704	3	6
116	Abstract MP36: Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis. <i>Hypertension</i> , 2020 , 76,	8.5	1
115	Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). <i>Cardiovascular Diabetology</i> , 2020 , 19, 164	8.7	43
114	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020 , 219, 47-57	4.9	14
113	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2020 , 43, 374-381	14.6	2
112	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 798-806	6.7	7
111	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020 , 43, 643-652	14.6	19

110	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020 , 220, 82-88	4.9	2
109	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020 , 43, 446-452	14.6	31
108	Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. <i>Endocrinology, Diabetes and Metabolism</i> , 2020 , 3, e00130	2.7	
107	Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. <i>Nature Communications</i> , 2020 , 11, 3766	17.4	20
106	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. <i>Diabetes Care</i> , 2020 , 43, 2493-2499	14.6	10
105	Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials. <i>Diabetologia</i> , 2020 , 63, 2482-2485	10.3	7
104	Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2493-2498	6.7	10
103	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. <i>Diabetes Care</i> , 2020 , 43, 2485-2492	14.6	2
102	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 138	8.7	25
101	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019 , 18, 116	8.7	9
100	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019 , 218, 57-65	4.9	3
99	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. <i>Circulation</i> , 2019 , 140, 1613-1622	16.7	26
98	Comment on Kim et al. The Effect of a Smartphone-Based, Patient-Centered Diabetes Care System in Patients With Type 2 Diabetes: A Randomized, Controlled Trial for 24 Weeks. <i>Diabetes Care</i> 2019;42:3-9. <i>Diabetes Care</i> , 2019 , 42, e125	14.6	1
97	Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> 2019;42:157-163. <i>Diabetes Care</i> , 2019 , 42, e95	14.6	
96	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. <i>International Journal of Cardiology</i> , 2019 , 289, 58-62	3.2	0
95	Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2115-2122	6.7	16
94	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2019 , 42, 1075-1080	14.6	7
93	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1576-1584	6.7	34

92	An outcome model approach to transporting a randomized controlled trial results to a target population. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019 , 26, 429-437	8.6	6
91	Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. <i>Cardiovascular Diabetology</i> , 2019 , 18, 135	8.7	6
90	Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2019 , 218, 92-99	4.9	1
89	Progression of glucose-lowering diabetes therapy in TECOS. <i>Endocrinology, Diabetes and Metabolism</i> , 2019 , 2, e00053	2.7	6
88	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e008018	6	15
87	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019 , 139, 863-873	16.7	8
86	Real-world studies no substitute for RCTs in establishing efficacy. <i>Lancet, The</i> , 2019 , 393, 210-211	4.0	56
85	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019 , 42, 318-326	14.6	20
84	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 69-74	3.2	1
83	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. <i>Diabetes Care</i> , 2018 , 41, 705-712	14.6	36
82	Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1427-1434	6.7	17
81	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a EditorsTExpert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
80	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018 , 41, 596-603	14.6	44
79	Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials. <i>Nature Reviews Endocrinology</i> , 2018 , 14, 67-68	15.2	1
78	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 105-113	18.1	336
77	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1732-1739	6.7	2
76	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. <i>American Heart Journal</i> , 2018 , 199, 170-175	4.9	4
75	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. <i>Diabetes Care</i> , 2018 , 41, 1844-1853	14.6	43

74	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes</i> , 2018 , 67, 522-P	0.9	34
73	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-64	4.4	21
72	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. <i>Circulation</i> , 2018 , 138, 2576-2578	16.7	9
71	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e009304	6	12
70	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 1519-1529	40	771
69	Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis. <i>Diabetes Care</i> , 2018 , 41, 1312-1320	14.6	41
68	What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?. <i>Journal of Diabetes</i> , 2018 , 10, 683-685	3	
67	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2379-2388	6.7	15
66	International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4
65	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes Care</i> , 2017 , 40, 494-501	14.6	40
64	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 859-863	3.2	2
63	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1587-1593	6.7	18
62	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). <i>Circulation</i> , 2017 , 136, 1193-1203	16.7	33
61	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 431-437	18.1	258
60	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017 , 187, 1-9	4.9	39
59	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017 , 40, 1763-1770	14.6	46
58	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. <i>Hypertension</i> , 2017 , 70, 907-914	8.5	10
57	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 877-886	18.1	164

56	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 1228-1239	59.2	1017
55	Microvascular outcomes in type 2 diabetes - AuthorsTreply. <i>Lancet Diabetes and Endocrinology,the</i> , 2017 , 5, 580	18.1	
54	Health selection into neighborhoods among patients enrolled in a clinical trial. <i>Preventive Medicine Reports</i> , 2017 , 8, 51-54	2.6	2
53	Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 356-363	6.7	35
52	Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 78-86	6.7	43
51	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017 , 40, 164-170	14.6	39
50	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care</i> , 2016 , 39, 2304-2310	14.6	114
49	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , 2016 , 174, 103-10	4.9	70
48	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 126-35	16.2	161
47	The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomised sub-study. <i>Diabetes Research and Clinical Practice</i> , 2016 , 120, 56-64	7.4	9
46	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016 , 48, 1055-1059	36.3	108
45	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015 , 373, 232-42	59.2	1739
44	The effect of glibenclamide on insulin secretion at normal glucose concentrations. <i>Diabetologia</i> , 2015 , 58, 43-9	10.3	7
43	Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 116-24	18.1	131
42	Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2014 , 10, 453-4	15.2	
41	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--AuthorsTreply. <i>Lancet, The</i> , 2014 , 384, 1097-8	40	4
40	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014 , 168, 23-9.e2	4.9	46
39	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 843-51	18.1	214

38	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet, The</i> , 2014 , 383, 2008-17	40	167
37	Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data. <i>Diabetes Care</i> , 2013 , 36, 1541-6	14.6	15
36	Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2013 , 166, 983-989.e7	4.9	107
35	A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. <i>American Journal of Cardiology</i> , 2013 , 112, 231-7	3	4
34	Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive. <i>Nature Reviews Endocrinology</i> , 2013 , 9, 67-8	15.2	30
33	Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. <i>Circulation</i> , 2013 , 127, 980-7	16.7	76
32	Evaluation of a self-administered oral glucose tolerance test. <i>Diabetes Care</i> , 2013 , 36, 1483-8	14.6	11
31	Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>Stroke</i> , 2013 , 44, 2590-3	6.7	8
30	Understanding the outcomes of multi-centre clinical trials: a qualitative study of health professional experiences and views. <i>Social Science and Medicine</i> , 2012 , 74, 574-81	5.1	31
29	Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice. <i>Practical Diabetes</i> , 2012 , 29, 61-64	0.7	1
28	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. <i>BMJ Open</i> , 2012 , 2,	3	19
27	Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial. <i>Trials</i> , 2011 , 12, 108	2.8	25
26	Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 1032-40	6.9	58
25	Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , 2010 , 362, 1477-90	59.2	493
24	Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial: an interview study of patients and health professionals' experiences. <i>Diabetes Care</i> , 2010 , 33, 2178-80	14.6	24
23	Effect of nateglinide on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , 2010 , 362, 1463-76	59.2	358
22	Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. <i>Cardiovascular Therapeutics</i> , 2010 , 28, 124-32	3.3	7
21	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. <i>Lancet, The</i> , 2010 , 375, 1365-74	40	188

20	Perceptions of heart attack risk amongst individuals with diabetes. <i>Primary Care Diabetes</i> , 2009 , 3, 239-44	4.4	5
19	Three-year efficacy of complex insulin regimens in type 2 diabetes. <i>New England Journal of Medicine</i> , 2009 , 361, 1736-47	59.2	522
18	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2009 , 32, 193-203	14.6	2432
17	Presenting the results of clinical trials to participants. <i>Clinical Medicine</i> , 2009 , 9, 415-6	1.9	4
16	10-year follow-up of intensive glucose control in type 2 diabetes. <i>New England Journal of Medicine</i> , 2008 , 359, 1577-89	59.2	5246
15	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. <i>American Heart Journal</i> , 2008 , 156, 623-32	4.9	72
14	Determining the most appropriate components for a composite clinical trial outcome. <i>American Heart Journal</i> , 2008 , 156, 633-40	4.9	33
13	Long-term follow-up after tight control of blood pressure in type 2 diabetes. <i>New England Journal of Medicine</i> , 2008 , 359, 1565-76	59.2	557
12	Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i> , 2008 , 31, 845-51	14.6	431
11	Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. <i>New England Journal of Medicine</i> , 2007 , 357, 1716-30	59.2	574
10	Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. <i>Diabetes Care</i> , 2007 , 30, 1292-3	14.6	137
9	Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <i>New England Journal of Medicine</i> , 2006 , 355, 2427-43	59.2	2332
8	Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2006 , 29, 1963-72	14.6	935
7	Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. <i>American Heart Journal</i> , 2006 , 152, 27-38	4.9	338
6	Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes. <i>Diabetes Care</i> , 2005 , 28, 1796-7	14.6	41
5	Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). <i>Diabetes Care</i> , 2002 , 25, 330-6	14.6	485
4	Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). <i>American Heart Journal</i> , 1999 , 138, S353-9	4.9	60
3	UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. <i>Lancet, The</i> , 1997 , 350, 1288-93	40	584

2	The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group. <i>Annals of Medicine</i> , 1996, 28, 439-44	1.5	34
1	Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical data		1